Display options
Cite
Dosset M, Vargas TR, Lagrange A, et al. PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncoimmunology. 2018;7(6):e1433981doi: 10.1080/2162402X.2018.1433981.
Dosset, M., Vargas, T. R., Lagrange, A., Boidot, R., Végran, F., Roussey, A., Chalmin, F., Dondaine, L., Paul, C., Lauret Marie-Joseph, E., Martin, F., Ryffel, B., Borg, C., Adotévi, O., Ghiringhelli, F., & Apetoh, L. (2018). PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncoimmunology, 7(6), e1433981. https://doi.org/10.1080/2162402X.2018.1433981
Dosset, Magalie, et al. "PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer." Oncoimmunology vol. 7,6 (2018): e1433981. doi: https://doi.org/10.1080/2162402X.2018.1433981
Dosset M, Vargas TR, Lagrange A, Boidot R, Végran F, Roussey A, Chalmin F, Dondaine L, Paul C, Lauret Marie-Joseph E, Martin F, Ryffel B, Borg C, Adotévi O, Ghiringhelli F, Apetoh L. PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncoimmunology. 2018 Mar 15;7(6):e1433981. doi: 10.1080/2162402X.2018.1433981. eCollection 2018. PMID: 29872568; PMCID: PMC5980491.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2018 Mar 15;7(6):e1433981. doi: 10.1080/2162402X.2018.1433981. eCollection 2018.

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.

Oncoimmunology

Magalie Dosset, Thaiz Rivera Vargas, Anaïs Lagrange, Romain Boidot, Frédérique Végran, Aurélie Roussey, Fanny Chalmin, Lucile Dondaine, Catherine Paul, Elodie Lauret Marie-Joseph, François Martin, Bernhard Ryffel, Christophe Borg, Olivier Adotévi, François Ghiringhelli, Lionel Apetoh

Affiliations

  1. INSERM, U1231, Dijon, France.
  2. INSERM, U1098, Besançon, France.
  3. LabEx LipSTIC, Besançon, France.
  4. Université de Bourgogne Franche Comté, Dijon, France.
  5. Centre Georges François Leclerc, Dijon, France.
  6. University of Cape Town, RSA, CNRS, UMR7355, Orleans, France, IDM.
  7. Department of Medical Oncology, University Hospital of Besançon, France.

PMID: 29872568 PMCID: PMC5980491 DOI: 10.1080/2162402X.2018.1433981

Abstract

BACKGROUND: Chemotherapy is currently evaluated in order to enhance the efficacy of immune checkpoint blockade (ICB) therapy in colorectal cancer. However, the mechanisms by which these drugs could synergize with ICB remains unclear. The impact of chemotherapy on the PD-1/PD-L1 pathway and the resulting anticancer immune responses was assessed in two mouse models of colorectal cancer and validated in tumor samples from metastatic colorectal cancer patients that received neoadjuvant treatment. We demonstrated that 5-Fluorouracil plus Oxaliplatin (Folfox) drove complete tumor cure in mice when combined to anti-PD-1 treatment, while each monotherapy failed. This synergistic effect relies on the ability of Folfox to induce tumor infiltration by activated PD-1

Keywords: CD8 T cells; PD-1/PD-L1 pathway; chemotherapy; colorectal cancer, adaptive immune resistance; immunotherapy

References

  1. Science. 2012 Nov 30;338(6111):1220-5 - PubMed
  2. Cell. 2015 Apr 9;161(2):205-14 - PubMed
  3. Oncoimmunology. 2015 Feb 25;4(4):e998538 - PubMed
  4. J Clin Invest. 2016 Sep 1;126(9):3447-52 - PubMed
  5. Nat Rev Cancer. 2016 May;16(5):275-87 - PubMed
  6. J Immunol. 2006 Dec 1;177(11):7515-9 - PubMed
  7. Nat Med. 2007 Sep;13(9):1050-9 - PubMed
  8. Nature. 2014 Nov 27;515(7528):568-71 - PubMed
  9. Immunity. 2016 Feb 16;44(2):343-54 - PubMed
  10. Cancer Discov. 2015 Sep;5(9):915-9 - PubMed
  11. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  12. Nat Rev Immunol. 2008 Jan;8(1):59-73 - PubMed
  13. J Immunol. 2011 Oct 15;187(8):4068-76 - PubMed
  14. Oncogene. 2010 Jan 28;29(4):482-91 - PubMed
  15. Nat Immunol. 2005 Dec;6(12):1236-44 - PubMed
  16. BMC Genomics. 2014 Mar 13;15:190 - PubMed
  17. FEBS Lett. 2006 Feb 6;580(3):755-62 - PubMed
  18. Nat Rev Cancer. 2012 Mar 22;12(4):252-64 - PubMed
  19. Immunity. 2016 May 17;44(5):989-1004 - PubMed
  20. Nature. 2017 Mar 30;543(7647):728-732 - PubMed
  21. Nature. 2017 Jan 18;541(7637):321-330 - PubMed
  22. Nat Immunol. 2011 May 29;12(7):663-71 - PubMed
  23. Autophagy. 2015;11(10):1878-90 - PubMed
  24. J Clin Oncol. 2005 Aug 1;23(22):4866-75 - PubMed
  25. Immunotherapy. 2011 Oct;3(10):1223-33 - PubMed
  26. Science. 2011 Dec 16;334(6062):1573-7 - PubMed
  27. Cancer Cell. 2015 Dec 14;28(6):690-714 - PubMed
  28. Clin Colorectal Cancer. 2005 Nov;5(4):263-7 - PubMed
  29. Ann Oncol. 2016 Mar;27(3):409-16 - PubMed
  30. Immunity. 2013 Jul 25;39(1):1-10 - PubMed
  31. N Engl J Med. 2015 Jun 25;372(26):2509-20 - PubMed
  32. Front Immunol. 2015 Apr 24;6:187 - PubMed
  33. Cancer Res. 2010 Apr 15;70(8):3052-61 - PubMed
  34. Immunity. 2016 Jun 21;44(6):1255-69 - PubMed
  35. Nat Rev Cancer. 2005 May;5(5):397-405 - PubMed

Publication Types